-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎WuXi AppTec content team editor
.
This effect may affect tumors and normal cells, and can strengthen the immune system in the body to detect and fight tumor cells
.
In September 2014, Keytruda was first approved in the United States for the treatment of advanced melanoma, becoming the first FDA-approved PD-1 inhibitor, and the drug has been approved for more than 30 indications
in the United States.
In China, Keytruda has previously been approved for multiple indications, including hepatocellular carcinoma
, which was approved just a month ago.
Merck (MSD) today announced the positive top-line results
of its blockbuster immunotherapy Keytruda (pembrolizumab) combination therapy in the treatment of gastric cancer.
Data analysis showed that this pivotal Phase 3 trial achieved the primary endpoint of significantly improving overall survival (OS)
regardless of PD-L1 expression in the patient's tumor.
Stomach cancer is the fifth most commonly diagnosed cancer and the fourth leading cause
of cancer death worldwide.
In 2020, there were nearly 1.
1 million newly diagnosed stomach cancer cases worldwide, resulting in 768,000 deaths
.
More than 70% of stomach cancer patients are diagnosed at an advanced stage, and the 5-year survival rate of these patients is only about 6%, and they are in urgent need of innovative therapies
.
.
This effect may affect tumors and normal cells, and can strengthen the immune system in the body to detect and fight tumor cells
.
In September 2014, Keytruda was first approved in the United States for the treatment of advanced melanoma, becoming the first FDA-approved PD-1 inhibitor, and the drug has been approved for more than 30 indications
in the United States.
In China, Keytruda has previously been approved for multiple indications, including hepatocellular carcinoma
, which was approved just a month ago.
The KEYNOTE-859 trial, which published results, is a double-blind, Phase 3 clinical trial with 1579 patients enrolled and randomized to receive either a combination of Keytruda/chemotherapy or a placebo/chemotherapy combination
.
Data analysis showed that the trial achieved the primary endpoint, with Keytruda combination therapy significantly improving overall survival compared to control in all randomly assigned patients
.
In addition, statistically significant and clinically significant improvements
in progression-free survival (PFS) and overall response rate (ORR) were observed in all patients receiving the combination therapy at the secondary endpoint of the trial.
In terms of security, Keytruda showed consistent results with no new safety signals
.
Image source: 123RF
"Despite improvements in cancer care, the five-year survival rate for advanced gastric cancer remains low, and patients urgently need new therapies
.
The results of the KEYNOTE-859 trial show that Keytruda in combination with chemotherapy has the potential to improve survival in patients with HER2-negative locally advanced unresectable, metastatic gastric cancer, or gastroesophageal junction (GEJ) adenocarcinoma compared to chemotherapy alone, regardless of the PD-L1 expression of their tumors," said Dr.
Eliav Barr, Chief Medical Officer, Head of Global Clinical Development and Senior Vice President, Merck Laboratories Alone.
This demonstrates our commitment to promoting Keytruda's new treatment for gastric cancer patients, and we are grateful
to all investors and patients who participated in the trial.
" ”
Resources:
[1] Merck Announces Phase 3 KEYNOTE-859 Trial Met Primary Endpoint of Overall Survival in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
Retrieved November 22, 2022 from style="margin-bottom: 0px;line-height: normal;">Disclaimer: WuXi AppTec's content team focuses on global biomedical health research progress
.
This article is for informational purposes only, and the views expressed in this article do not represent the position of WuXi AppTec, nor do they represent WuXi AppTec's support or disapproval of the views
expressed herein.
This article is also not a treatment recommendation
.
For guidance on treatment options, go to a regular hospital
.
